In a previous blog on the use of psychedelics to treat mental health disorders, we reported that the US Food and Drug Administration (FDA) granted breakthrough therapy designation to MDMA (a.k.a., ecstasy) in 2017 as part of...more
We live in an era in which we can instantly obtain copious amounts of information quickly through the internet, and while this has many advantages, it also opens the door for potential problems. Just search for the term “fake...more
Tens of millions of Americans suffer from nasal and sinus congestion every year. People had come to rely on an increasing number of over-the-counter nasal decongestants to relieve their symptoms. The active ingredient in...more
A growing problem in the U.S. is the widespread availability of counterfeit medications, or fake prescription pills. These drugs, made to look like authentic prescription medications, may contain no active ingredient or any...more
Hypertension, or high blood pressure, is commonly diagnosed among the middle-aged and elderly population. In individuals aged 40-59 years, there is a prevalence of 54.5%. In individuals aged ≥60 years, there is a prevalence...more
In August of 2017, the FDA granted breakthrough therapy designation to MDMA (a.k.a., Ecstasy/Molly) for the treatment of Post-Traumatic Stress Disorder (PTSD). Just recently the results of the first Phase 3 clinical trial...more
Although many states have legalized marijuana for medicinal and/or recreational use, when it comes to using marijuana in a research setting, sources have been very limited. The US Drug Enforcement Administration (DEA) has...more
6/24/2021
/ Agribusiness ,
Cannabis Products ,
Clinical Trials ,
DEA ,
Essential Health Benefits ,
Marijuana ,
Marijuana Cultivation ,
Memorandum of Agreement ,
NIDA ,
Research and Development ,
Scientific Research